Bruker Corporation Welcomes Diagnostics Industry Leader Jack Phillips to Board of Directors

In a significant move to strengthen its leadership, Bruker Corporation (Nasdaq: BRKR) announced today that Jack J. Phillips will be joining its Board of Directors effective January 1, 2026. With over three decades of experience in the diagnostics sector, Phillips is expected to bring invaluable insights and strategic guidance to the company.

Jack Phillips has an impressive track record in the healthcare industry, particularly in diagnostics. His most recent role was as President & CEO of Accelerate Diagnostics from 2020 to 2025, where he was instrumental in pioneering rapid antibiotic susceptibility testing (AST) technology. This innovation has been crucial for hospitals and infectious disease specialists in the fight against serious bacterial infections, life-threatening sepsis, and antibiotic resistance.

Prior to his tenure at Accelerate Diagnostics, Phillips served as President & CEO of Roche Diagnostics North America from 2010 to 2020. Under his leadership, Roche solidified its position as a leader in the global in vitro diagnostics (IVD) industry, overseeing a diverse portfolio that included clinical chemistry, immunodiagnostics, molecular diagnostics, and digital pathology.

Phillips also held the position of Senior Vice President and General Manager for North America at Ventana Medical Systems from 1999 to 2010, where he played a key role in establishing tissue and companion diagnostics as standards of care.

Frank H. Laukien, Bruker's chairman, president, and CEO, expressed enthusiasm about Phillips' appointment: “Bruker is delighted to add Jack to our board of directors. His broad and deep diagnostics experience, strategic acumen, and market development experience will be very valuable to Bruker and our board."

Laukien highlighted the timely nature of Phillips' addition, particularly as Bruker seeks to broaden its infectious disease diagnostics portfolio and leverage its unique disease biology research tools for opportunities in specialty diagnostics.

Jack Phillips himself commented on the honor of joining Bruker's Board: “It’s a great honor to join the Board of Directors at Bruker Corporation, a company with an entrepreneurial culture and a unique dedication to innovation and translation that I really admire. Throughout my career, I've seen diagnostics not as siloed technologies, but as a connected ecosystem that turns biological insight into clinical and economic impact.”

Bruker Corporation has positioned itself as a leader in the post-genomic era, enabling scientists and engineers to achieve breakthrough discoveries through high-performance scientific instruments and diagnostic solutions. The addition of Phillips to the board aligns with Bruker's commitment to innovation and excellence in the life sciences and diagnostics sectors.

As Bruker continues to enhance its offerings in clinical microbiology and molecular diagnostics, Phillips' expertise in translating scientific innovations into clinical impact will be pivotal in driving the company's growth and expanding its influence in the healthcare landscape.

The appointment of Jack J. Phillips to Bruker's Board of Directors marks a strategic move that underscores the company's commitment to strengthening its leadership in the diagnostics industry. With a seasoned executive at the helm, Bruker is poised for continued success in delivering innovative solutions that improve patient outcomes and drive business growth.